Accelovance, Inc. Continues Geographic and Service Expansion with Acquisition of Clinquest, Inc. & BV

ROCKVILLE, Maryland and BOSTON and AMSTERDAM, Dec. 2, 2015 /PRNewswire/ -- Accelovance, Inc. (Accelovance), a global contract research organization (CRO) focusing in oncology, vaccines, and general medicine clinical research; today announced it has acquired Clinquest, Inc. (US) and Clinquest Services BV (the Netherlands) (Clinquest) from Clinquest Group BV. With offices in 's-Hertogenbosch, the Netherlands, and Boston, MA; Clinquest provides clinical research, data management/biostatistics, medical information, and pharmacovigilance services to the pharmaceutical and biotech industries. The acquisition continues the expansion of Accelovance's existing US and European footprint while also providing the company with extensive expertise in pharmacovigilance services.

Logo - []

"Accelovance is pleased to have Clinquest's talented employees and loyal client base join us as part of our continued expansion. We look forward to the contributions of our new associates, the opportunity to continue great work with Clinquest's current clients, and in having a seasoned and experienced drug development specialist and inflammatory disease Key Opinion Leader such as Cornelis (Cees) Wortel, MD, PhD, as part of our team," said Stephen J. Trevisan, President and CEO of Accelovance. "This acquisition supports Accelovance's geographic expansion and grows our talent base across functional and therapeutic areas to better serve and meet the development needs of our clients."

Clinquest has been providing CRO services to the pharmaceutical industry for more than 15 years, focusing on comprehensive clinical development and pre- and post-marketing pharmacovigilance services. "We're excited to be joining Accelovance and to be contributing to their growth and expansion. This is a great match and benefits both our employees and customers and allows us to offer our areas of expertise, especially in data management/biostatistics and pharmacovigilance services, to an expanded set of drug development clients," said Cornelis Wortel, MD, PhD, Founder and Chief Medical Officer of Clinquest.

About Accelovance

Accelovance, Inc., headquartered in Rockville, MD, is an industry award-winning Contract Research Organization (CRO) focused primarily in oncology, vaccines, and general medicine clinical research. As a clinical services provider to the pharmaceutical and biotechnology industries, Accelovance offers comprehensive clinical development services including management and implementation of Phase I-IV clinical trials and a clinical engagement solution utilized for recruitment, post-marketing surveillance, and long-term survival follow-up. For more information, visit the company's Web site at [].

Press Contact: Michael Keens, VP Business Development 240.238.4941 Twitter: @Accelovance


Web site:

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234